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The prevalence, clinical presentation, and risk factors for hyperlactatemia among patients receiving antire-
troviral therapy was determined during a 1-month period for patients in the Swiss HIV Cohort Study. Overall,
73 (8.3%) of 880 patients presented an increase in serum lactate of 11.1 times the upper normal limit (UNL).
For 9 patients (1%), lactate elevation was moderate or severe (12.2 times the UNL). Patients who presented
with hyperlactatemia were more likely to be receiving stavudine with or without didanosine (odds ratio, 2.7;
95% confidence interval, 1.5–4.8), as compared with patients who received zidovudine-based regimens. The
risk increased with increasing time receiving stavudine with or without didanosine. The association between
hyperlactatemia and stavudine with or without didanosine was not biased by these medications being more
recently available and, therefore, being given preferentially to patients who had prolonged use of nucleoside
analog reverse-transcriptase inhibitors. Hyperlactatemia was associated with lipoatrophy, hyperlipidemia, and
hyperglycemia. Age, sex, or stage of infection with human immunodeficiency virus were not predictive of
hyperlactatemia. Determination of lactate levels may prove useful in the screening for mitochondrial toxicity.
Identification and characterization of novel forms of
toxicity—clinical presentation, spectrum of severity,
and risk factors—has become a priority, because pro-
longed use of antiretrovirals makes long-term toxicity
a critical issue for the treatment of HIV-infected pa-
tients. Hyperlactatemia is an increasingly recognized
adverse effect of antiretroviral therapy (ART) for which
only few data exist.
HIV-associated disorders of lactic acid metabolism
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were first described in the early 1990s. Originally re-
ported as rare instances of lactic acidosis and hepatic
failure associated with the use of didanosine [1], they
were later described in association with use of most of
the available nucleoside analog reverse-transcriptase in-
hibitors (NRTIs) [2–7]. More recently, disorders such
as myopathy, neuropathy, and pancreatitis have been
proposed as part of a common spectrum of toxicity [2,
8–11]. Carr et al. [3] described the association of lactic
acidemia and hepatic dysfunction with a fat redistri-
bution syndrome dominated by lipoatrophy and weight
loss. NRTIs are thought to induce mitochondrial tox-
icity by inhibiting the nuclear polymerase g, resulting
in depletion of mitochondrial DNA and damage of the
respiratory chain [8, 12–15].
In the present study, we aimed to do the following:
(1) estimate the prevalence of hyperlactatemia in a large
observational cohort of HIV-infected patients receiving
ART; (2) identify the severity and the spectrum of lab-
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oratory and clinical abnormalities associated with increased lac-
tate levels; and (3) assess factors associated with the presence
of this metabolic abnormality.
PATIENTS AND METHODS
Swiss HIV Cohort Study. The Swiss HIV Cohort Study (SHCS;
see http://www.shcs.ch) enrolls HIV-infected people aged 16
years. Patients are followed up in 1 of 7 study centers (Basel,
Bern, Geneva, Lausanne, Lugano, St. Gall, and Zurich). Data are
collected according to a common protocol at registration and at
follow-up visits scheduled at 6-month intervals. CD4 cell count
is measured by means of flow cytometry, and virus load is de-
termined using the Roche Amplicor Monitor assay (Roche Di-
agnostic; level of detection, !20 or 400 copies/mL).
Study design. To determine the period prevalence of ad-
verse events among SHCS participants receiving ART, a cross-
sectional study was conducted during a 4-week period in Au-
gust and September 1999; it included all SHCS participants
receiving potent ART, with the exception of patients who started
or switched a regimen within the previous 30 days. A ques-
tionnaire based on the classification of adverse events used by
the AIDS Clinical Trials Group was completed by the doctor
during the outpatient visit. Patients were explicitly asked by
their doctors if symptoms itemized in the questionnaire oc-
curred within the 30 days preceding the visit. Potential adverse
events were scored according to a severity score (grades 1–4,
or mild, moderate, severe, and serious, respectively), and the
likelihood of adverse events being related to ART (“definitely
not attributed,” “possible,” “probable,” and “definitive”), fol-
lowing the definition of causality of the World Health Organ-
ization (http://www.who-umc.org/defs.html), was assessed.Def-
inition of lipodystrophy (lipoatrophy and fat accumulation)
was based on doctors’ examinations, as indicated in the study
protocol.
“Contemporary treatment” was defined as the treatment that
the patient was receiving at the time of the study visit. “Con-
temporary treatment exposure” referred to the length of con-
tinuous exposure to the contemporary drug regimen. “Total
NRTI exposure” was defined as the cumulative exposure time
to each single agent.
Laboratory tests. For all participants, we proposed mea-
surement of the following values: hemoglobin, neutrophil and
platelet count, creatinine, urate, serum transaminases, alkaline
phosphatase, bilirubin, pancreatic amylase, creatinine phos-
phokinase, glucose, triglycerides, cholesterol, and proteinuria.
Abnormal findings of laboratory evaluations were reported as
“mild,” “moderate,” and “severe” in relation to the normal limit
of each variable. Normal limits are defined as the central interval
of 95% (between 2.5 and 97.5 percentiles) of the values of healthy
people. Blood sampling for lactate determination was performed
after removal of the tourniquet in tubes containing sodium flu-
oride [16]. A “mild augmentation of blood lactate” was defined
as 1.1–2 times the upper normal limit (UNL); “moderate” was
defined as 2.1–3 times the UNL; “severe,” as 3.1–4 times the
UNL; and “serious,” as 14 times the UNL. For glucose, trigly-
ceride, and cholesterol determinations, actual values in the fasting
or nonfasting state were used for analysis.
Statistical analysis. Univariate assessment of risk factors
for hyperlactatemia, including previous or concurrent treat-
ment with specific drugs, was conducted using the x2 test, for
categorical variables, and t test, for continuous variables. To
further measure the independent association between these var-
iables and hyperlactatemia, we used multiple logistic regression.
Variables significantly associated with the outcome in the uni-
variate analysis as well as variables that were clinically relevant
were included in the initial models. Two specific models were
developed to assess the role of individual drugs and the role
of drug combinations in hyperlactatemia. Models were then
simplified by means of a backward stepwise approach. Variables
considered in the final model were age, sex, most recent CD4
cell count and virus RNA load value, duration of total NRTI
exposure, and relevant antiretroviral combinations.
RESULTS
Subjects. Data from 1359 patients receiving ART were ob-
tained; 880 of these patients had a valid blood lactate mea-
surement. Patients included in the study represented 33% of
the 4151 actively followed-up patients in the SHCS at the time
of the study. Patients included were more advanced in the
course of illness than were patients who were not seen at the
time of the study (data not shown). A lactate determination
was not available for 479 patients because laboratory testing
had been performed before the study visit, because of the doc-
tor’s decision, because of patient refusal, or because of poor
compliance with the specifications for blood sampling for lac-
tate determination with sodium fluoride tubes. There were no
significant differences between participants with or without lac-
tate measurement in terms of demographic characteristics, HIV
disease-specific parameters, or type of ART.
Overall, 73 (8.3%) of 880 patients had an elevated lactate
level (mild in 64 patients and moderate in 9). One patient’s
condition evolved to severe lactic acidosis and multiorgan fail-
ure. There were no demographic, virologic, or immunologic
differences between participants who had increased or normal
lactate values (table 1).
Antiretroviral agents and hyperlactatemia. Analysis of
the antiretroviral agents used at the time of lactate determi-
nation (contemporary treatment) identified stavudine and di-
danosine to be associated with an increased risk of hyperlac-
tatemia, whereas zidovudine and lamivudine were associated
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Table 1. Characteristics of patients with and without hyperlactatemia.
Characteristic
Patient lactate level
Pa
Increased
(n p 73)
Normal
(n p 807)
Male sex 54 (74) 587 (73) .820
CDC group .581
A 24 (33) 310 (38)
B 24 (33) 260 (32)
C 25 (34) 237 (29)
Risk group .052
Men who have sex with men 30 (41) 337 (42)
Heterosexual transmission 28 (38) 232 (29)
Injection drug use 9 (12) 205 (25)
Other 3 (4) 19 (2)
Age, mean years  SD 42.8  1.2 40.7  0.3 .056
Body mass index, mean  SD 22.3  0.4 22.8  0.1 .220
Most recent CD4 cell count,
mean cells/mm3  SD 428  38.2 414  9.3 .848
CD4 nadir, mean cells/mm3 SD 359  39.3 339  10.0 .694
Most recent RNA measurement,
mean copies/mL  SD 8771  3857 18697  3499 .352
NOTE. Data are no. (%) of patients, unless otherwise indicated. CDC, Centers for
Disease Control and Prevention.
a P values were determined using Pearson x2, for categorical variables, and t test, for
continuous variables.
with a lower risk (table 2). To study the impact of specific drug
combinations, 7 groups of ART were determined a priori. Three
were regimens that contained zidovudine, and 4 were regimens
with combinations of stavudine with or without didanosine.
Overall, hyperlactatemia was determined in 54 (11.1%) of 485
patients who received regimens that included stavudine with
or without didanosine and in 15 (4.2%) of 361 patients who
received regimens that contained zidovudine. Figure 1 sum-
marizes the results and identifies hyperlactatemia associated
with use of regimens that contain stavudine with or without
didanosine (OR, 2.7; 95% CI, 1.5–4.8), as compared with reg-
imens that contain zidovudine. Hyperlactemia was not asso-
ciated with stavudine regimens without concomitant didano-
sine administration (OR, 1.6; 95% CI, 0.8–3.2). Only 28
patients were receiving didanosine without concomitant ad-
ministration of stavudine, and no increased risk for hyperlac-
tatemia could be demonstrated for this small group of patients
(OR, 2.6; 95% CI, 0.5–13.1).
We assessed the possibility that previous exposure to other
NRTI agents was responsible for the observed rates of hyper-
lactatemia in patients who were receiving stavudine with or
without didanosine. For this, only patients starting a first-ever
treatment with a regimen that contained zidovudine (232 pa-
tients) or an ART that contained stavudine with or without
didanosine (187 patients) were included in the analysis. This
confirmed that treatment-naı¨ve patients who developed hy-
perlactatemia were more likely to have received stavudine with
or without didanosine (OR, 5.6; 95% CI, 2.3–13.6) than an
ART that contained zidovudine as first treatment.
For patients who were receiving stavudine with or without
didanosine, the risk of hyperlactatemia increased from OR 0.9
(95% CI, 0.3–2.9), for patients with !6-month contemporary
exposure, to OR 3.7 (95% CI, 12.0–6.9), for patients receiving
6–24 months of therapy, when compared with regimens that
contain zidovudine in an analysis adjusted for age, sex, most
recent CD4 and viremia values, and total NRTI exposure. Pa-
tients with 124 months of consecutive exposure to stavudine
did not experience an additional increase in risk. No such as-
sociation between duration of contemporary treatment and hy-
perlactatemia was identified for other agents (data not shown).
Association with clinical and laboratory findings. An as-
sociation was identified between lipoatrophy (fat loss in the
face, arm, leg, and buttocks) and hyperlactatemia (table 3).
Multivariate analysis (including the variables described in the
“Patients and Methods” section) confirmed this association:
patients with hyperlactatemia had a greater likelihood of li-
poatrophy than did patients without lactate elevation (OR 1.8;
95% CI, 1.1–3.0).
A significant association was also identified between elevated
urate levels, a phenomenon described elsewhere in association
with use of didanosine [17], plasma glucose, cholesterol and
triglycerides, and hyperlactatemia (table 4). The association be-
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Table 2. Present therapy, according to substance and hyper-
lactatemia status.
Substance
No. (%) of patients,
by lactate level
Crude OR
(95% CI) P
Increased
(n p 73)
Normal
(n p 807)
Zidovudine 17 (23) 344 (43) 0.4 (0.2–0.7) .002
Lamivudine 34 (47) 559 (69) 0.4 (0.2–0.6) !.001
Stavudine 54 (74) 431 (53) 2.5 (1.4–4.3) .001
Didanosine 33 (45) 161 (20) 3.3 (2.0–5.4) !.001
Abacavir 6 (8) 66 (8) 1.0 (0.4–2.4) .99
Efavirenz 14 (19) 96 (12) 1.8 (0.9–3.3) .08
Nevirapine 4 (5) 35 (4) 1.3 (0.4–3.7) .59
Indinavir 10 (14) 158 (20) 0.7 (0.3–1.3) .17
Ritonavir 10 (14) 163 (20) 0.6 (0.3–1.3) .20
Saquinavir 7 (10) 118 (15) 0.6 (0.3–1.4) .29
Nelfinavir 35 (48) 352 (44) 1.2 (0.7–1.9) .43
Amprenavir 2 (3) 10 (1) 2.3 (0.5–10.5) .28
Hydroxyurea 4 (5) 18 (2) 2.5 (0.8–7.7) .10
Figure 1. Drug combinations in current therapy and hyperlactatemia. ORs were calculated by means of logistic-regression adjusted for age, sex,
most recent CD4 cell count, most recent RNA value, and previous exposure to nucleoside analog reverse-transcriptase inhibitors. Not shown are the
combinations zidovudine (AZT), a protease inhibitor (PI), and efavirenz (EFV; ); didanosine (DDI) and AZT combinations (n p 12); or DDI-onlynp 12
combinations ( ). Other, use of stavudine (D4T) or AZT in monotherapy or in combination therapy including agents other than a PI or EFV; ,np 16
with or without.
tween dyslipidemia and hyperlactatemia remained for the sub-
set of patients for whom determinations were performed in the
fasting state (data not shown). The association with proteinuria
was not retained in a multivariate analysis.
DISCUSSION
Lactate, one of the components of the respiratory chain, is
produced during the glycolytic pathway as a product of trans-
formation of pyruvate. When the oxygen supply of tissues is
sufficient, the metabolism of pyruvate is primarily oxidative,
with no intracellular accumulation of lactate. Impairment of
oxygen supply or cytoplasmic accumulation of pyruvate may
result in increased lactate formation. Hyperlactatemia is char-
acterized by mild to moderate increases in blood lactate con-
centration without metabolic acidosis. Lactic acidosis is defined
by persistently increased blood lactate levels (usually 15 mmol/
L) in association with acidosis (pH !7.35) [18]. Hyperlacta-
temia is also a marker for altered mitochondrial function [19].
Acquired or congenital abnormalities of mitochondrial oxi-
dative phosphorylation result in a broad spectrum of clinical
disorders, including peripheral neuropathy, encephalopathy,
sensorineural deafness, myopathy, cardiomyopathy and con-
duction defects, pancreatitis and diabetes mellitus, liver stea-
tosis, renal tubular dysfunction, pancytopenia, and multiple
systemic lipomas [13, 19].
NRTIs are a substrate of the cellular polymerase g. Inhibition
of the polymerase results in decreasing levels of mitochondrial
DNA and, thus, a diminished synthesis of mitochondrial en-
zymes (reviewed in [13]). The relative affinity of the various
NRTIs for the polymerase g, and their capacity for mitochon-
drial damage remains controversial [20, 21].
Here, we provide an analysis of the prevalence of hyperlac-
tatemia in a large observational study. It underscores the fre-
quency of mild elevations of lactate in blood and confirms the
association between lactate elevation and various clinical man-
ifestations. In the SHCS study, the mean lactate value (SD)
was mmol/L for patients receiving ART versus1.56 0.736
mmol/L for treatment-naı¨ve people. Similar data1.24 0.529
have been recently described from an Australian cohort [22].
A probable syndrome of NRTI toxicity includes metabolic and
lipid disorders. In addition, we confirm reports published else-
where [23] regarding the association with the atrophic mani-
festations of lipodystrophy disorders (45% of patients with el-
evated lactate levels in the present study).
The study allowed the scoring of different antiretrovirals,
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Table 3. Clinical symptoms and hyperlactatemia.
Symptom
No. (%) of patients,
by lactate level
Crude OR
(95% CI) P
Increased
(n p 73)
Normal
(n p 807)
Fever 1 (1) 29 (4) 0.4 (0.1–3.0) .37
Headache 9 (12) 184 (23) 0.5 (0.2–1.0) .07
Fatigue 24 (33) 282 (35) 0.9 (0.5–1.5) .64
Lithiasis 2 (3) 6 (1) 3.8 (0.7–19.7) .11
Rash 4 (6) 54 (7) 0.9 (0.3–2.5) .78
Myositis 2 (3) 12 (1) 1.8 (0.4–8.5) .45
Nausea 15 (21) 140 (17) 1.3 (0.7–2.3) .43
Vomiting 7 (10) 67 (8) 1.3 (0.6–2.9) .56
Diarrhea 27 (37) 342 (42) 0.8 (0.5–1.3) .33
Mood disorders 14 (19) 193 (24) 0.7 (0.4–1.4) .33
Paresthesia 15 (21) 126 (16) 1.3 (0.7–2.4) .38
Neuromotor disorders 7 (10) 40 (5) 1.9 (0.8–4.5) .15
Sleep disorders 11 (15) 142 (18) 0.8 (0.4–1.6) .62
Fat loss
Facial 28 (38) 153 (19) 2.8 (1.7–4.7) !.001
Arm 23 (32) 119 (15) 2.6 (1.5–4.5) .001
Leg 26 (36) 131 (16) 2.9 (1.7–5.0) !.001
Buttocks 16 (22) 112 (14) 1.6 (0.9–2.9) .13
Abdomen fat gain 14 (19) 236 (29) 0.5 (0.3–1.0) .04
Buffalo hump 2 (3) 18 (2) 1.2 (0.3–5.3) .84
Breast enlargement 6 (8) 55 (7) 1.3 (0.5–3.1) .60
Parotid enlargement 2 (3) 12 (1) 1.7 (0.4–8.0) .50
Lipoatrophy, any sign 33 (45) 219 (27) 2.2 (1.3–3.7) .002
Fat accumulation, any sign 17 (23) 251 (31) 0.6 (0.4–1.1) .11
singularly and in combination, in terms of their relative and
independent association with hyperlactatemia. There was an
increased likelihood of hyperlactatemia in patients who were
receiving regimens that contained stavudine with or without
didanosine, as compared with regimens that contained zido-
vudine. Toxicity of didanosine and stavudine combinations may
be further aggravated in the presence of hydroxyurea [11].
Analyses were adjusted for duration of exposure to NRTI
and confirmed in the subgroup of patients having never re-
ceived zidovudine before the present treatment with stavudine
with or without didanosine. Thus, the observed association
between hyperlactatemia and stavudine with or without di-
danosine should not be biased by these medications being more
recently added to the therapeutic armamentarium and, there-
fore, given preferentially to patients who have had prolonged
NRTI use.
Errors in the determination of lactate levels were identified
in the course of the present study and led to the exclusion of
data from 91 patients from analysis. Although lactate values
remain stable for at least 8 h at room temperature in tubes
containing sodium fluoride [16], blood lactate levels may be
spuriously increased by the ischemia caused by a tourniquet or
storage of blood without sodium fluoride.
The present study provides information on the complex issue
of lipodystrophy [23], and it reveals associations between hy-
perlactatemia, fat atrophy, and specific ART regimens. It also
suggests that differences in the reporting of lipodystrophy rates
between countries and studies may reflect differences in the
pattern of antiretroviral drug use. An evaluation at a single time
point does not allow analysis of the natural history of the
putative mitochondrial disorder. In particular, there was 1 sin-
gle instance of lactic acidosis and hepatic steatosis; therefore,
there is no basis for an analysis of risk factors of these com-
plications. However, a recent report indicates that hyperlacta-
temia in patients receiving ART usually has a chronic, com-
pensated, and asymptomatic evolution [22].
Future studies should analyze the role of routine lactic acid
determination in the management of HIV-infected patients re-
ceiving ART, particularly those presenting with hepatic, neu-
rologic, and metabolic disturbances. Randomized intervention
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Table 4. Laboratory disorders and values associated with hyperlactatemia.
Characteristic
No. of
patients
with
available
data
Patients with
Crude OR
(95% CI) P
Increased
lactate
level
(n p 73)
Normal
lactate
level
(n p 807)
Laboratory disorder
Decreased hemoglobin 868 3 (4) 13 (2) 2.7 (0.8–9.7) .10
Decreased neutrophil count 874 2 (3) 38 (5) 0.6 (0.1–2.5) .53
Decreased platelet count 874 0 (0) 45 (6) — —
Increased creatinine 833 2 (3) 27 (3) 0.9 (0.2–3.8) .74
Proteinuria 714 13 (18) 69 (9) 2.3 (1.2–4.4) .01
Increased urate 862 37 (51) 193 (24) 3.5 (2.1–5.7) !.001
Increased alanine aminotransferase 864 11 (15) 180 (22) 0.6 (0.3–1.2) .19
Increased aspartate aminotransferase 440 9 (12) 80 (10) 1.3 (0.6–2.7) .37
Alkaline phosphatase 874 10 (14) 86 (11) 1.3 (0.7–2.7) .45
Increased bilirubin 866 7 (10) 65 (8) 1.3 (0.6–2.8) .65
Increased amylase 867 2 (3) 36 (4) 0.6 (0.2–2.6) .57
Increased creatine phosphokinase 863 4 (5) 52 (6) 0.9 (0.3–2.5) .83
Laboratory values, mean  SEM
Glucose 870 5.87  0.3 4.99  0.05 — !.001a
Cholesterol 860 5.97  0.2 5.57  0.05 — .03a
Triglyceride 859 2.77  0.09 2.25  0.7 — !.001a
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Determined using the t test.
protocols will be required to establish the relative value of treat-
ment interruption; treatment modification from stavudine with
or without didanosine to regimens containing zidovudine, la-
mivudine, or abacavir; or combination therapies excluding
NRTIs. The value of riboflavin or other cofactors of the res-
piratory chain [24–26] in reversing lactate accumulation also
needs evaluation.
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